NCT05054140Phase 2Unknown

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Study sponsor: Immunic AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-01-07Estimated
Enrollment · participants450Estimated
Source updated2024-04-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview